Evogene to Showcase Generative AI Drug Design at Schrödinger Conference
Event summary
- Evogene presenting at 24th Schrödinger European User Group Meeting in Munich, May 19–21, 2026.
- Dr. Roberto Olender, Head of Algorithms, to discuss multi-objective GenAI foundation model for de novo molecule design.
- Session co-features Sanofi, highlighting competitive positioning in computational drug discovery.
- Event focuses on small molecule drug design advancements through generative AI technologies.
The big picture
Evogene's participation in this high-profile conference underscores the growing importance of generative AI in drug discovery. As computational chemistry tools become more sophisticated, the ability to design novel compounds efficiently is becoming a key differentiator in the pharmaceutical industry. This event provides Evogene with a platform to demonstrate its technological capabilities and potentially attract new partnerships or investment.
What we're watching
- Technology Validation
- How Evogene's presentation will be received by industry peers and potential partners.
- Competitive Positioning
- Whether Evogene can differentiate its ChemPass AI technology against competitors like Sanofi.
- Partnership Opportunities
- The pace at which Evogene can translate conference engagement into collaborative agreements.
Related topics